Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$144.41 USD

144.41
697,861

-0.75 (-0.52%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $144.35 -0.06 (-0.04%) 7:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ALNY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Alnylam Pharmaceuticals, Inc. [ALNY]

Reports for Purchase

Showing records 261 - 280 ( 406 total )

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 261

08/15/2012

Daily Note

Pages: 3

Regulus Secures Deal with AstraZeneca

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 262

08/10/2012

Industry Report

Pages: 5

BIOTECHNOLOGY BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 263

08/08/2012

Company Report

Pages: 7

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 264

08/06/2012

Daily Note

Pages: 3

Reports 2Q12 Results and Reviews Recent Clinical Successes

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 265

08/06/2012

Company Report

Pages: 8

Reports 2Q12 Results and Reviews Recent Clinical Successes

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 266

07/30/2012

Daily Note

Pages: 3

Progress of the VaxiRNA Program Illustrates the Robustness

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 267

07/30/2012

Company Report

Pages: 5

Progress of the VaxiRNA Program Illustrates the Robustness

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 268

07/26/2012

Company Report

Pages: 7

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 269

07/17/2012

Company Report

Pages: 6

Updating Our Models; Raising Price Target

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 270

07/17/2012

Daily Note

Pages: 3

Updating Our Models

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 271

07/16/2012

Daily Note

Pages: 3

Phase I Shows the Goods

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 272

07/16/2012

Company Report

Pages: 5

Phase I Shows the Goods

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 273

07/16/2012

Company Report

Pages: 8

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 274

07/11/2012

Company Report

Pages: 7

Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 275

07/11/2012

Daily Note

Pages: 3

Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 276

07/10/2012

Company Report

Pages: 5

Upcoming TTR-02 Data Should Provide Near-Term Catalyst to ALNY Shares

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 277

06/12/2012

Daily Note

Pages: 3

Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 278

06/12/2012

Company Report

Pages: 4

Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 279

05/30/2012

Company Report

Pages: 4

Phase II Data Breathes Life into ALN-RSV01, For Now

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 280

05/30/2012

Daily Note

Pages: 3

Phase II Data Breathes Life into ALN-RSV01, For Now

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party